stockportfolio.pro
Organon & Co. (OGN)
Healthcare · Drug Manufacturers - General · NYSE
Organon & Co. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $7.78B | $6.53B | $6.30B | $6.17B | $6.26B | $6.40B | $6.22B |
| Gross profit | $5.50B | $4.41B | $3.92B | $3.88B | $3.75B | $3.71B | $3.31B |
| Net income | $3.22B | $2.16B | $1.35B | $917.00M | $1.02B | $864.00M | $187.00M |
| Net margin | 41.4% | 33.1% | 21.4% | 14.9% | 16.3% | 13.5% | 3.0% |
Source: Organon & Co. SEC filings (10-K).
Explore 7 years of Organon & Co. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track OGN in your portfolio →
About Organon & Co.
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Organon & Co. — frequently asked questions
What is Organon & Co.'s revenue?
Organon & Co. (OGN) reported revenue of $6.22B for fiscal year 2025, down 2.9% from the prior year, according to its SEC filings.
Is Organon & Co. profitable?
Yes. OGN earned net income of $187.00M in fiscal 2025, a net margin of 3.0%.
What is OGN's P/E ratio?
Organon & Co. trades at a price-to-earnings ratio of about 14.4 based on the latest data in our nightly-refreshed cache.
How fast is Organon & Co. growing?
OGN's revenue grew at roughly -1.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Organon & Co.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.